Kazia Therapeutics Announces Two Abstracts on Paxalisib Tumor and Immune Reprogramming Research Accepted for Poster Presentation at 2026 San Antonio Breast Cancer Symposium
PR Newswire•02/11/2026•07:00 ET
0
Key Highlights
- ➤Two paxalisib abstracts accepted for 2026 San Antonio Breast Cancer Symposium posters
- ➤Paxalisib showed distinct tumor and immune reprogramming versus other dual PI3K/mTOR inhibitors
- ➤Preclinical stage III TNBC model research found suppressed local and metastatic recurrence
- ➤Presentations examine paxalisib after standard neoadjuvant chemo-immunotherapy
Kazia Therapeutics Announces Two Abstracts on Paxalisib Tumor and Immune Reprogramming Research Accepted for Poster Presentation at 2026 San Antonio Breast Cancer Symposium PR Newswire
Presentations to Explore Paxalisib's Differentiated Tumor and Immune Reprogramming Activity
Get started
Create a free account to read the full story.